These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 31243042)

  • 1. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
    Taylor J; Haddadin M; Upadhyay VA; Grussie E; Mehta-Shah N; Brunner AM; Louissaint A; Lovitch SB; Dogan A; Fathi AT; Stone RM; Tallman MS; Rampal RK; Neuberg DS; Stevenson KE; Horwitz SM; Lane AA
    Blood; 2019 Aug; 134(8):678-687. PubMed ID: 31243042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jain A; Sweet K
    J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
    Lee SS; McCue D; Pemmaraju N
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
    Economides MP; Rizzieri D; Pemmaraju N
    Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
    Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
    Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic Cell Leukemia: a Review.
    Tsagarakis NJ; Paterakis G
    Curr Oncol Rep; 2020 May; 22(6):55. PubMed ID: 32415624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review.
    Wang Y; Xiao L; Yin L; Zhou L; Deng Y; Deng H
    Medicine (Baltimore); 2023 Feb; 102(7):e32904. PubMed ID: 36800625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment.
    Sweet K
    Curr Opin Hematol; 2020 Mar; 27(2):103-107. PubMed ID: 31972688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights.
    Venugopal S; Zhou S; El Jamal SM; Lane AA; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):545-554. PubMed ID: 31281107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
    Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
    Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Alfayez M; Konopleva M; Pemmaraju N
    Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379
    [No Abstract]   [Full Text] [Related]  

  • 14. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
    Wang S; Wang X; Liu M; Bai O
    Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature.
    Liao C; Hu NX; Song H; Zhang JY; Shen DY; Xu XJ; Tang YM
    Int J Hematol; 2021 May; 113(5):751-759. PubMed ID: 33392975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm.
    Falcone U; Sibai H; Deotare U
    Crit Rev Oncol Hematol; 2016 Nov; 107():156-162. PubMed ID: 27823644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained remission of blastic plasmacytoid dendritic cell neoplasm after unrelated allogeneic stem cell transplantation--a single center experience.
    Heinicke T; Hütten H; Kalinski T; Franke I; Bonnekoh B; Fischer T
    Ann Hematol; 2015 Feb; 94(2):283-7. PubMed ID: 25138222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
    Riaz W; Zhang L; Horna P; Sokol L
    Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
    Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Wilson NR; Pemmaraju N
    Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.